27600888|t|Uveitis in spondyloarthritis patients and its association with HLA-B27 histocompatibility antigen: prospective study
27600888|a|T o perform a prospective study of clinical presentation and course of uveitis in spondyloarthritis (SpA) patients as well as its association with the HLA-B27 histocompatibility antigen. The study included 219 patients with uveitis, all tested for HLA-B27 antigen and various infections (viral, bacterial, and parasitic) as well as examined for locomotive system involvement. The presence of the HLA-B27 antigen was determined in 142 (64.8%) out of 219 patients, of them 87 were diagnosed with an entity of the SpA group. The remaining 77 (35.2%) patients appeared to be HLA-B27 - negative, but 13 were still diagnosed with an entity of the SpA group. There were 10 (4.6%) patients with 2 or more diseases from the SpA group («clinical decussation»). When comparing the two groups of HLA-B27-positive and negative patients having both SpA and uveitis, no statistically significant difference was found as to the age of onset, site, frequency of attacks, and uni - or bilateral involvement (p>0.05). We also performed a comparison of HLA-B27-positive and negative patients with no account to their SpA status and revealed a higher complication rate in those that were « negative » (p<0.0001), which can be explained by the fact that HLA-B27 - negative patients often have autoimmune or infectious uveitis of different origin notable for long attacks and short remissions. Assessing the site and course of uveitis as well as HLA-B27 testing of uveitis patients has proved important for etiological diagnosis. Diseases of the SpA group have been shown to be 6.7 times more common in HLA-B27-positive patients as compared to HLA-B27 - negative ones. Clinical presentation of uveitis in the presence of SpA in both HLA-B27-positive and negative patients resembles that of idiopathic uveitis - an independent HLA-B27 - associated syndrome (р>0.05). Cases of «decussation» between entities of the SpA group are usually more severe in terms of clinical presentation and course of uveitis and are associated with a worse prognosis. Complications of uveitis are more likely to be found in non-SpA HLA-B27 - negative patients (р<0.0001).
27600888	0	7	Uveitis	T047	C0042164
27600888	11	28	spondyloarthritis	T047	C0949690
27600888	29	37	patients	T101	C0030705
27600888	46	62	association with	T080	C0332281
27600888	63	97	HLA-B27 histocompatibility antigen	T116,T129	C0019740
27600888	99	116	prospective study	T062	C0033522
27600888	131	148	prospective study	T062	C0033522
27600888	152	173	clinical presentation	T170	C2708283
27600888	178	184	course	T079	C0750729
27600888	188	195	uveitis	T047	C0042164
27600888	199	216	spondyloarthritis	T047	C0949690
27600888	218	221	SpA	T047	C0949690
27600888	223	231	patients	T101	C0030705
27600888	247	263	association with	T080	C0332281
27600888	268	302	HLA-B27 histocompatibility antigen	T116,T129	C0019740
27600888	308	313	study	T062	C2603343
27600888	327	335	patients	T101	C0030705
27600888	341	348	uveitis	T047	C0042164
27600888	354	360	tested	T169	C0039593
27600888	365	380	HLA-B27 antigen	T116,T129	C0019740
27600888	393	403	infections	T046	C3714514
27600888	405	410	viral	T047	C0042769
27600888	412	421	bacterial	T047	C0004623
27600888	427	436	parasitic	T047	C0747256
27600888	449	457	examined	T033	C0332128
27600888	462	479	locomotive system	T022	C0026860
27600888	480	491	involvement	T169	C1314939
27600888	497	505	presence	T033	C0150312
27600888	513	528	HLA-B27 antigen	T116,T129	C0019740
27600888	533	543	determined	T080	C0521095
27600888	570	578	patients	T101	C0030705
27600888	596	605	diagnosed	T033	C0011900
27600888	614	620	entity	T071	C1551338
27600888	628	631	SpA	T047	C0949690
27600888	632	637	group	T078	C0441833
27600888	643	652	remaining	T080	C1527428
27600888	664	672	patients	T101	C0030705
27600888	688	695	HLA-B27	T116,T129	C0019740
27600888	698	706	negative	T033	C0205160
27600888	726	735	diagnosed	T033	C0011900
27600888	744	750	entity	T071	C1551338
27600888	758	761	SpA	T047	C0949690
27600888	762	767	group	T078	C0441833
27600888	790	798	patients	T101	C0030705
27600888	814	822	diseases	T047	C0012634
27600888	832	835	SpA	T047	C0949690
27600888	836	841	group	T078	C0441833
27600888	873	882	comparing	T052	C1707455
27600888	891	897	groups	T078	C0441833
27600888	901	917	HLA-B27-positive	T034	C0239961
27600888	922	930	negative	T033	C0205160
27600888	931	939	patients	T101	C0030705
27600888	952	955	SpA	T047	C0949690
27600888	960	967	uveitis	T047	C0042164
27600888	972	997	statistically significant	T081	C0237881
27600888	998	1008	difference	T080	C1705242
27600888	1029	1041	age of onset	T081	C0206132
27600888	1043	1047	site	T029	C1515974
27600888	1049	1069	frequency of attacks	T079	C0439603
27600888	1075	1078	uni	T082	C0205092
27600888	1084	1093	bilateral	T082	C0238767
27600888	1094	1105	involvement	T169	C1314939
27600888	1124	1133	performed	T169	C0884358
27600888	1136	1146	comparison	T052	C1707455
27600888	1150	1166	HLA-B27-positive	T034	C0239961
27600888	1171	1179	negative	T033	C0205160
27600888	1180	1188	patients	T101	C0030705
27600888	1214	1217	SpA	T047	C0949690
27600888	1218	1224	status	T080	C0449438
27600888	1229	1237	revealed	T080	C0443289
27600888	1240	1246	higher	T080	C0205250
27600888	1247	1259	complication	T046	C0009566
27600888	1260	1264	rate	T081	C1521828
27600888	1286	1294	negative	T033	C0205160
27600888	1349	1356	HLA-B27	T116,T129	C0019740
27600888	1359	1367	negative	T033	C0205160
27600888	1368	1376	patients	T101	C0030705
27600888	1388	1398	autoimmune	T047	C3888523
27600888	1402	1420	infectious uveitis	T047	C0042164
27600888	1424	1433	different	T080	C1705242
27600888	1453	1457	long	T080	C0205166
27600888	1470	1475	short	T081	C1806781
27600888	1476	1486	remissions	T033	C0544452
27600888	1488	1497	Assessing	T058	C0184514
27600888	1502	1506	site	T029	C1515974
27600888	1511	1517	course	T079	C0750729
27600888	1521	1528	uveitis	T047	C0042164
27600888	1540	1547	HLA-B27	T116,T129	C0019740
27600888	1548	1555	testing	T169	C0039593
27600888	1559	1566	uveitis	T047	C0042164
27600888	1567	1575	patients	T101	C0030705
27600888	1587	1596	important	T080	C3898777
27600888	1601	1612	etiological	T169	C1314792
27600888	1613	1622	diagnosis	T033	C0011900
27600888	1624	1632	Diseases	T047	C0012634
27600888	1640	1643	SpA	T047	C0949690
27600888	1644	1649	group	T078	C0441833
27600888	1676	1681	times	T081	C1632851
27600888	1697	1713	HLA-B27-positive	T034	C0239961
27600888	1714	1722	patients	T101	C0030705
27600888	1726	1734	compared	T052	C1707455
27600888	1738	1745	HLA-B27	T116,T129	C0019740
27600888	1748	1756	negative	T033	C0205160
27600888	1763	1784	Clinical presentation	T170	C2708283
27600888	1788	1795	uveitis	T047	C0042164
27600888	1803	1811	presence	T033	C0150312
27600888	1815	1818	SpA	T047	C0949690
27600888	1827	1843	HLA-B27-positive	T034	C0239961
27600888	1848	1856	negative	T033	C0205160
27600888	1857	1865	patients	T101	C0030705
27600888	1884	1902	idiopathic uveitis	T047	C0042164
27600888	1920	1927	HLA-B27	T116,T129	C0019740
27600888	1930	1940	associated	T080	C0332281
27600888	1941	1949	syndrome	T047	C0039082
27600888	1991	1999	entities	T071	C1551338
27600888	2007	2010	SpA	T047	C0949690
27600888	2011	2016	group	T078	C0441833
27600888	2034	2040	severe	T080	C0205082
27600888	2053	2074	clinical presentation	T170	C2708283
27600888	2079	2085	course	T079	C0750729
27600888	2089	2096	uveitis	T047	C0042164
27600888	2105	2120	associated with	T080	C0332281
27600888	2123	2138	worse prognosis	T033	C0278252
27600888	2140	2153	Complications	T046	C0009566
27600888	2157	2164	uveitis	T047	C0042164
27600888	2196	2203	non-SpA	T033	C0243095
27600888	2204	2211	HLA-B27	T116,T129	C0019740
27600888	2214	2222	negative	T033	C0205160
27600888	2223	2231	patients	T101	C0030705